Welcome to our dedicated page for CRESCO LABS news (Ticker: CRLBF), a resource for investors and traders seeking the latest updates and insights on CRESCO LABS stock.
Cresco Labs Inc. reports developments in branded cannabis products, retail dispensaries, cultivation, production and state-regulated market access. The company operates Sunnyside dispensaries and distributes cannabis brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi.
Recurring updates cover quarterly financial results, dispensary openings, medical and adult-use market activity, cannabis licensing matters and operational growth initiatives. Company communications also address branded product distribution, retail execution, balance sheet and cash-flow themes, community outreach, workforce development and legislative or regulatory engagement in the cannabis industry.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Bridgeport at 435 Main Street, Bridgeport, Ohio on April 10, 2026. It is Cresco Labs' seventh dispensary in Ohio and its 73rd across the U.S.
The store is open daily 9 a.m.–9 p.m., sells Cresco Labs brands including Cresco, Supply, Good News, Mindy’s and Wonder, and offers online ordering for pickup at www.sunnyside.shop.
Cresco Labs (OTCQX: CRLBF) announced on April 2, 2026 that it was conditionally awarded a Texas Compassionate Use Program license. The vertically integrated license permits Cresco Labs to cultivate, process and dispense medical cannabis in Texas.
The company said the award supports its state-by-state growth strategy, enables capital-efficient market entry through organic licensing, and secures access to Texas’s ~30 million residents as patient access evolves.
Cresco Labs (OTCQX: CRLBF) reported Q4 2025 revenue of $162 million and fiscal 2025 revenue of $656 million, with strengthened margins and cash generation. Adjusted EBITDA was $40 million in Q4 and $157 million for the year. Operating cash flow was $27 million in Q4 and $73 million for the year.
The company posted a FY net loss of $140 million and Q4 net loss of $89 million reflecting one-time, non-cash impairment charges. Cash and equivalents totaled $91 million and senior secured term loan debt was $311 million.
Cresco Labs (OTCQX: CRLBF) will report full year and fourth quarter 2025 financial results on Thursday, March 5, 2026 before the market opens. A conference call and webcast are scheduled at 8:30 am ET to discuss results and business highlights.
Archived webcast access will be available for one year on the investor relations website. Dial-in and registration details are provided for investors.
Cresco Labs (OTCQX: CRLBF) entered an equity distribution agreement with Haywood Securities to establish an at-the-market (ATM) program to sell up to ~US$100 million (C$140 million) of subordinate voting shares.
Proceeds are intended for general corporate purposes, including potential acquisitions; no shares have been sold to date. The program is offered under a prospectus supplement dated January 29, 2026, and sales will occur on Canadian marketplaces in compliance with applicable securities laws.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Tamarac at 6001 N University Drive in Tamarac, Florida, marking its 31st dispensary in Florida and 72nd location nationwide.
The store offers products from Cresco Labs' brand portfolio including Cresco, FloraCal, Supply, Good News, Remedi and Sunnyside, plus accessories; orders can be placed in store or online at www.sunnyside.shop. Store hours: Monday–Friday 9:00 a.m.–8:00 p.m.; Sunday 9:00 a.m.–6:00 p.m.
Cresco Labs (OTCQX: CRLBF) issued a CEO statement after President Trump rescheduled cannabis from Schedule I to Schedule III under the Controlled Substances Act on December 18, 2025. The company called the move a historic shift that enables expanded medical research, eases the industry's federal tax burden, and advances banking reform and U.S. capital market access. The statement cited public support figures and noted implications for the estimated 450,000 workers in the regulated cannabis industry.
Cresco Labs (OTCQX: CRLBF) announced on November 12, 2025 the commercial launch of Cresco-branded flower in Germany, marking the company's first entry into the European Union.
The company is piloting three signature flower products, partnered with Blossom, an EU GMP-certified manufacturer in Portugal, and will distribute products via prescription through licensed pharmacies across Germany. The launch is presented as a market-entry pilot to gather insights to guide future international expansion.
Cresco Labs (OTCQX: CRLBF) reported Q3 2025 revenue of $165 million and gross profit of $79 million, with an Adjusted gross margin of 48.8%. The company posted Adjusted EBITDA of $40 million (24.1% margin) and operating cash flow of $6 million, while reporting a net loss of $22 million that included a $16 million loss on debt extinguishment and $2 million impairment charges. On August 13, 2025, Cresco closed a refinancing: a new $325 million senior secured term loan at 12.5% interest maturing August 13, 2030, used to repay a prior $360 million facility. Cash and equivalents totaled $79 million at quarter end.
Cresco Labs (OTCQX: CRLBF) will report third quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, November 5, 2025 before the market opens.
The company will host an earnings conference call and webcast on the same day at 8:30 am ET to discuss results and provide investor highlights. Dial-in numbers, an access code, registration links, and a webcast link are provided for live participation. The webcast archive will be available for one year on the Cresco Labs investor relations website.